EMEA-000649-PIP01-09 - paediatric investigation plan

taspoglutide
PIPHuman

Key facts

Active substance
taspoglutide
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/80/2010
PIP number
EMEA-000649-PIP01-09
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Ipsen Pharma

E-mail: paediatrics.plans@ispen.com
Tel. +33 1 5833 5000

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date
Compliance check done
No

Decision

Share this page